tetano
Editor, Senior Moderator
N Engl J Med
. 2024 Jul 18;391(3):224-234.
doi: 10.1056/NEJMoa2309002. Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19
Jennifer Hammond[SUP] 1 [/SUP], Carla Yunis[SUP] 1 [/SUP], Robert J Fountaine[SUP] 1 [/SUP], Gerald Luscan[SUP] 1 [/SUP], Aimee M Burr[SUP] 1 [/SUP], Wuyan Zhang[SUP] 1 [/SUP], Wayne Wisemandle[SUP] 1 [/SUP], Holly Soares[SUP] 1 [/SUP], Mary Lynn Baniecki[SUP] 1 [/SUP], Victoria M Hendrick[SUP] 1 [/SUP], Veselin Kalfov[SUP] 1 [/SUP], Rienk Pypstra[SUP] 1 [/SUP], James M Rusnak[SUP] 1 [/SUP]
Affiliations
Background: Clinical trials of treatments for coronavirus disease 2019 (Covid-19) have not shown a significant benefit of postexposure prophylaxis.
Methods: We conducted a phase 2-3 double-blind trial to assess the efficacy and safety of nirmatrelvir-ritonavir in asymptomatic, rapid antigen test-negative adults who had been exposed to a household contact with Covid-19 within 96 hours before randomization. The participants were randomly assigned in a 1:1:1 ratio to receive nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir) every 12 hours for 5 days or for 10 days or matching placebo for 5 or 10 days. The primary end point was the development of symptomatic SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection, confirmed on reverse-transcriptase-polymerase-chain-reaction (RT-PCR) or rapid antigen testing, through 14 days in participants who had a negative RT-PCR test at baseline.
Results: A total of 2736 participants were randomly assigned to a trial group - 921 to the 5-day nirmatrelvir-ritonavir group, 917 to the 10-day nirmatrelvir-ritonavir group, and 898 to the placebo group. Symptomatic, confirmed SARS-CoV-2 infection developed by day 14 in 2.6% of the participants in the 5-day nirmatrelvir-ritonavir group, 2.4% of those in the 10-day nirmatrelvir-ritonavir group, and 3.9% of those in the placebo group. In each nirmatrelvir-ritonavir group, the percentage of participants in whom symptomatic, confirmed SARS-CoV-2 infection developed did not differ significantly from that in the placebo group, with risk reductions relative to placebo of 29.8% (95% confidence interval [CI], -16.7 to 57.8; P = 0.17) in the 5-day nirmatrelvir-ritonavir group and 35.5% (95% CI, -11.5 to 62.7; P = 0.12) in the 10-day nirmatrelvir-ritonavir group. The incidence of adverse events was similar across the trial groups, with dysgeusia being the most frequently reported adverse event (in 5.9% and 6.8% of the participants in the 5-day and 10-day nirmatrelvir-ritonavir groups, respectively, and in 0.7% of those in the placebo group).
Conclusions: In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.).
. 2024 Jul 18;391(3):224-234.
doi: 10.1056/NEJMoa2309002. Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19
Jennifer Hammond[SUP] 1 [/SUP], Carla Yunis[SUP] 1 [/SUP], Robert J Fountaine[SUP] 1 [/SUP], Gerald Luscan[SUP] 1 [/SUP], Aimee M Burr[SUP] 1 [/SUP], Wuyan Zhang[SUP] 1 [/SUP], Wayne Wisemandle[SUP] 1 [/SUP], Holly Soares[SUP] 1 [/SUP], Mary Lynn Baniecki[SUP] 1 [/SUP], Victoria M Hendrick[SUP] 1 [/SUP], Veselin Kalfov[SUP] 1 [/SUP], Rienk Pypstra[SUP] 1 [/SUP], James M Rusnak[SUP] 1 [/SUP]
Affiliations
- PMID: 39018532
- DOI: 10.1056/NEJMoa2309002
Background: Clinical trials of treatments for coronavirus disease 2019 (Covid-19) have not shown a significant benefit of postexposure prophylaxis.
Methods: We conducted a phase 2-3 double-blind trial to assess the efficacy and safety of nirmatrelvir-ritonavir in asymptomatic, rapid antigen test-negative adults who had been exposed to a household contact with Covid-19 within 96 hours before randomization. The participants were randomly assigned in a 1:1:1 ratio to receive nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir) every 12 hours for 5 days or for 10 days or matching placebo for 5 or 10 days. The primary end point was the development of symptomatic SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection, confirmed on reverse-transcriptase-polymerase-chain-reaction (RT-PCR) or rapid antigen testing, through 14 days in participants who had a negative RT-PCR test at baseline.
Results: A total of 2736 participants were randomly assigned to a trial group - 921 to the 5-day nirmatrelvir-ritonavir group, 917 to the 10-day nirmatrelvir-ritonavir group, and 898 to the placebo group. Symptomatic, confirmed SARS-CoV-2 infection developed by day 14 in 2.6% of the participants in the 5-day nirmatrelvir-ritonavir group, 2.4% of those in the 10-day nirmatrelvir-ritonavir group, and 3.9% of those in the placebo group. In each nirmatrelvir-ritonavir group, the percentage of participants in whom symptomatic, confirmed SARS-CoV-2 infection developed did not differ significantly from that in the placebo group, with risk reductions relative to placebo of 29.8% (95% confidence interval [CI], -16.7 to 57.8; P = 0.17) in the 5-day nirmatrelvir-ritonavir group and 35.5% (95% CI, -11.5 to 62.7; P = 0.12) in the 10-day nirmatrelvir-ritonavir group. The incidence of adverse events was similar across the trial groups, with dysgeusia being the most frequently reported adverse event (in 5.9% and 6.8% of the participants in the 5-day and 10-day nirmatrelvir-ritonavir groups, respectively, and in 0.7% of those in the placebo group).
Conclusions: In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.).